Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis Full Text
American Journal of Respiratory and Critical Care Medicine,  Clinical Article

Koh WJ et al. – Levofloxacin (LFX) and moxifloxacin (MXF) are the two most frequently recommended fluoroquinolones for treatment of patients with multidrug–resistant tuberculosis (MDR–TB). The study aims to compare the effectiveness of LFX and MXF in terms of culture conversion after 3months of treatment for MDR–TB. The choice of LFX or MXF for treatment of patients with MDR–TB may not affect sputum culture conversion at 3months of treatment.


  • In this prospective multicenter randomized open label trial, the authors randomly assigned 182 patients with MDR-TB (sensitive to LFX and MXF) to receive either LFX (750mg/day; 90 patients) or MXF (400mg/day; 92 patients) with a background drug regimen.
  • The primary outcome was the proportion of patients who achieved sputum culture conversion at 3months of treatment.
  • Secondary outcomes were time to culture conversion and time to smear conversion, with data censored at 3months, and the proportions of adverse drug reactions.


  • At 3 months of treatment, 68 (88.3%) of the 77 patients in the LFX group and 67 (90.5%) of the 74 in the MXF group showed conversion to negative sputum cultures (odds ratio for LFX compared with MXF, 0.78; 95% confidence interval, 0.27-2.20).
  • Adverse drug reactions were reported in six patients (7.7%) in the LFX group and four (5.2%) in the MXF group (P=0.75).

Please login or register to follow this author.
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Pulmonology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Pulmonology Articles

1 Hookah smoke exposure doubles dangerous benzene uptake American Association for Cancer Research News, December 1, 2014

2 Early data suggests potentially severe flu season Full Text CDC, December 5, 2014    Free full text

3 The cellular origin of fibrosis Harvard Gazette - Health News, November 24, 2014

4 Multicentric study on the beta-blocker use and relation with exacerbations in COPD Respiratory Medicine, June 19, 2014    Clinical Article

5 Cytotoxic agents in sarcoidosis: Which one should we choose? Current Opinion in Pulmonary Medicine, August 15, 2014    Review Article

6 Is non-invasive ventilation safe in acute severe asthma? Respirology, November 11, 2014    Review Article

7 Prognostic severity scores for patients with COPD exacerbations attending emergency departments The International Journal of Tuberculosis and Lung Disease, November 21, 2014    Clinical Article

8 Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): A randomised, double-blind, placebo-controlled trial The Lancet Respiratory Medicine, May 15, 2014    Clinical Article

9 Adult asthmatics increase the risk of acute coronary syndrome: A nationwide population-based cohort study European Journal of Internal Medicine , November 25, 2014    Clinical Article

10 Efficacy and safety of a fixed-dose combination of indacaterol and glycopyrronium for the treatment of COPD: A systematic review Chest, August 21, 2014    Evidence Based Medicine

11 Fish intake and risk of chronic obstructive pulmonary disease in 2 large U.S. cohorts American Journal of Clinical Nutrition, December 11, 2014    Clinical Article

12 Endobronchial ultrasound-guided transbronchial needle aspiration for diagnosis of sarcoidosis in clinically unselected study populations Respirology, December 9, 2014    Evidence Based Medicine

13 Risk factors for 1-year relapse of pulmonary tuberculosis treated with a 6-month daily regimen Respiratory Medicine, February 3, 2014    Clinical Article

14 Quantifying the real life risk profile of inhaled corticosteroids in COPD by record linkage analysis Full Text Respiratory Research, December 1, 2014    Free full text    Clinical Article

15 Prophylactic antibiotic therapy after inhalation injury Burns, October 10, 2014    Clinical Article

16 Prevalence of chronic obstructive pulmonary disease among US working adults aged 40 to 70 years: National Health Interview Survey data 2004 to 2011 Journal of Occupational and Environmental Medicine, October 17, 2014    Clinical Article

17 Biomarker-based asthma phenotypes of corticosteroid response The Journal of Allergy and Clinical Immunology, December 8, 2014    Clinical Article

18 Chronic Cough: An Update Mayo Clinic Proceedings, October 3, 2013    Review Article    Clinical Article

19 Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: Impact on survival and bacterial resistance Critical Care, November 8, 2013    Clinical Article

20 The association between chronic obstructive pulmonary disease and Parkinson's disease: A nationwide population-based retrospective cohort study QJM: An International Journal of Medicine, July 18, 2014    Clinical Article

Indexed Journals in Pulmonology: Chest, Thorax, American Journal of Respiratory and Critical Care Medicinemore

Looking for a physician job? Let us help!

Register now for our free job placement service.
A career consultant will contact you soon.
Click Here for more information.

Get Started Now!

Free-of-charge, no obligation.

Terms and Conditions For M3 Career Consult

By registering with the M3 Career Consult service you authorize M3 USA Corporation to represent you in your job search. The following is a summary of the terms of our service and our mutual obligations to help you find a job:

  • You designate M3 to act as your agent and represent you in your job search;
  • You will not pay us for this service
  • You will advise us of any companies or positions to which you apply or have applied;
  • You will advise us if you believe you are not capable of performing a position for which we submit you, or for which you interview;
  • You will keep all information we provide you about companies or positions strictly confidential;
  • You will promptly provide us with information we request of you;
  • You will make yourself reasonably available for phone, video and in-person conversations and interviews;
  • You will be truthful in all of your communications with us; and
  • You will advise us if anything above changes.

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List